Analysis of the Level of Free-Circulating DNA and Exercise Tolerance in Patients with Chronic Heart Failure
In the course of this work, the level of fcDNA in the blood of patients with chronic heart failure (CHF) was analyzed with the main clinical and laboratory parameters: the level of natriuretic brain propeptide (NT-proBNP), as well as with the functional class (FC) and assessment of life quality according to the Minnesota questionnaire (MHFLQ). The study group included 90 people, of which 67 people had a diagnosis of CHF, and 23 people were healthy volunteers. All patients underwent the necessary examination, including a biochemical blood test with the determination of lipid spectrum, glucose, creatinine and NT-proBNP, as well as ECG registration and echocardiography. The next diagnostic step was a 6-minute walk test with calculation of the distance and determination of the functional class, as well as self-completion of the Minnesota questionnaire by patients in order to study the quality of life. The level of fcDNA was determined by the method of Laktionov P.P., Tamkovich S.N., Rykova E.Yu., 2005. The data obtained indicate a direct relationship between the subjective and objective state of the patient, while the decrease in the functional capabilities is accompanied by a progressive increase in laboratory markers. The problem of CHF remains actual medical and social problem, which requires further study. The search for new diagnostic methods that make it possible to characterize in more detail the condition of a patient suffering from this disease undoubtedly remains one of the highest priority tasks. Further study of the issue is necessary not only to expand diagnostic capabilities, but also for prognostic assessment of the clinical situation, taking into account the individual characteristics of the patient.
Kolesnikova E.V., Myachina O.V., Pashkov A.N. 2023. Analysis of the Level of Free-Circulating DNA and Exercise Tolerance in Patients with Chronic Heart Failure. Challenges in Modern Medicine. 46 (3): 219–230 (in Russian). DOI: 10.52575/2687-0940-2023-46-3-219-230
While nobody left any comments to this publication.
You can be first.
Ageev F.T., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Badin Yu.M., Galyavich A.S. et al., 2006. The prevalence of chronic heart failure in the European part of the Russian Federation – EPOCHA-CHF data. Journal of Heart Failure, 7 (1): 4–7 (in Russian).
Alieva A.M., Teplova N.V., Kislyakov V.A. 2022. Extracellular DNA and cardiovascular diseases. Russian medical journal, 5: 26–29 (in Russian).
Alieva A.M., Reznik E.V., Gasanova E.T., Zhbanov I.V., Nikitin I.G. 2018. Clinical significance of determining blood biomarkers in patients with chronic heart failure. Archives of Internal Medicine, 8 (5): 333-345. doi: 10.20514/2226-6704-2018-8-5-333-345 (in Russian).
Bondarchuk S.V., Ionova T.I., Odin V.I., Polyakov A.S., Kovalev A.V.2020. Principy` i metody` issledovaniya kachestva zhizni v medicine: uchebnoe posobie dlya vrachej-specialistov voenno-medicinskix organizacij [Principles and methods for studying the quality of life in medicine: a textbook for medical specialists of military medical organizations]. SPb, VMedA, 102.
Kozhevnikova M.V., Belenkov Yu.N. 2021. Biomarkers in Heart Failure: Current and Future. Kardiologiia, 61 (5): 4–16 (in Russian).
Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A., Gendlin G.E., Glezer M.G., Gotye S.V., Dovzhenko T.V., Kobalava Zh.D., Koziolova N.A., Koroteev A.V., Mareev Yu.V., Ovchinnikov A.G., Perepech N.B., Tarlovskaya E.I., Chesnikova A.I., Shevchenko A.O., Arutyunov G.P., Belenkov Yu.N., Galyavich A.S., Gilyarevsky S.R., Drapkina O.M., Duplyakov D.V., Lopatin Yu.M., Sitnikova M.Yu., Skibitsky V.V., Shlyakhto E.V. 2018. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Cardiology, 58 (6S): 8–158 (in Russian).
Mikheeva O.O., Domogatsky S.P., Efremov E.E., Esipov R.S. 2018. Molecular markers for diagnostics of cardiac failure. Russian Cardiology Bulletin, 13 (4): 62–67 (in Russian).
Trofimova E.A., Kireeva V.V., Usoltsev Yu.K., Kirilchik S.V., Lepekhova S.A., Apartsin K.A. 2022. Circulating free DNA in hypertensive patients with high cardiovascular risk. Russian journal of cardiology, 27 (4): 4709 (in Russian).
Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology 2020, 25 (11): 4083 (in Russian). doi:10.15829/1560-4071-2020-4083
Bayés-Genis A., Lanfear David E., de Ronde Maurice W.J., Lupón J., Leenders J.J., Liu Zhen, Zuithoff Nicolaas P.A., Eijkemans Marinus J.C., Zamora E., De Antonio Marta, Zwinderman A.H., Pinto-Sietsma Sara-Joan, Pinto Yigal M. 2018. Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients. European Journal of Heart Failure, 20 (1): 67–75. doi: 10.1002/ejhf.984
Califf R.M. 2018. Biomarker definitions and their applications. Experimental Biology and Medicine, 243 (3): 213–221. doi:10.1177/1535370217750088
Chen Y.-T., Wong L.L., Liew O.W., Richards M.A. 2019. Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs. Cells, 8 (12): 1651. doi: 10.3390/cells8121651
Cunningham J.W., Claggett B., O’Meara E., Prescott M., Pfeffer M. et al. 2020. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. Journal of the American College of Cardiology, 76 (5): 503–514. doi: 10.1016/j.jacc.2020.05.072
De Boer R.A., Nayor M., Christopher R. et al. 2018. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol, 3 (3): 215–224. doi:10.1001/jamacardio.2017.4987
Dasari T.W., Patel B., Wayangankar S.A. et al. 2020. Prognostic Value of 6-Minute Walk Distance in Patients Undergoing Percutaneous Coronary Intervention: a Veterans Affairs Prospective Study. Tex Heart Inst. J., 47 (1): 10–14. doi: 10.14503/THIJ-17-6471.
Devaux Y. 2020. Cardiomyocyte-Specific Cell-Free DNA as a Heart Failure Biomarker? Can. J. Cardiol., 36 (6): 807–808.
Haller N., Helmig S., Taenny P., Petry J., Schmidt S., Simon P. 2018. Circulating, cell-free DNA as a marker for exercise load in intermittent sports. PLoS ONE, 13 (1).
Karabulut A., Kaplan A., Aslan C., Iltumur K., Toprak G., Toprak N. 2005. The association between NT-proBNP levels, functional capacity and stage in patients with heart failure. Acta Cardiol., 60 (6): 631–638. doi: 10.2143/ac.60.6.2004936
Mannheimer B., Andersson B., Carlsson L., Währborg P. 2007. The validation of a new quality of life questionnaire for patients with congestive heart failure – an extension of the Cardiac Health Profile. Scand. Cardiovasc. J., 41: 235–241. doi: 10.1080/14017430701422454
Mueller C., McDonald K., de Boer R.A., Maisel A., Cleland J., Kozhuharov N., Coatset A. et al. 2019. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 21 (6): 715–731. doi: 10.1002/ejhf.1494
Polina I.A., Ilatovskaya D.V., DeLeon-Pennell K.Y. 2020. Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases. Clin. Chim. Acta., 503: 145–150. doi: 10.1016/j.cca.2020.01.013
Rector T.S., Kubo, Cohn J.N. 1987. Patients self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota living with heart failure questionnaire. Heart failure, 10: 198–209.
Sherwood K., Weimer E.T. 2018. Characteristics, properties, and potential applications of circulating cell-free DNA in clinical diagnostics: a focus on transplantation. J. Immunol. Methods, 463: 27–38. doi: 10.1016/j.jim.2018.09.011
Toukhsati S.R., Mathews S., Sheed A., Freijah I., Moncur L., Cropper P., Ha F.J., Hare D.L. 2019. Confirming a beneficial effect of the six-minute walk test on exercise confidence in patients with heart failure. Eur. J. Cardiovasc. Nurs., 1 (7): 165–71. doi: 10.1177/1474515119876784.
Troughton R., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. 2000. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet, 355: 1126–1130. doi: 10.1016/s0140-6736(00)02060-2
Tsao C.W., Lyass A., Enserro D., Larson M.G., Ho J.E., Kizer J.R., Gottdiener J.S., Psaty B.M., Vasan R.S. 2018. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart. Fail, 6: 678–685. doi: 10.1016/j.jchf.2018.03.006
Xie J., Yang J., Hu P. 2018. Correlations of Circulating Cell-Free DNA with Clinical Manifestations in Acute Myocardial Infarction. Am. J. Med. Sci., 356 (2): 121–129. doi: 10.1016/j.amjms.2018.04.007
Zemmour H., Planer D., Magenheim J., Moss J., Neiman D., Gilon D. et al. 2018. Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA. Nat Commun., 9 (1): 1443. doi: 10.1038/s41467-018-03961-y